(Q34643681)

3 August 2017

1 reference

title

Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin (English)

1 reference

3 August 2017

1 reference

David R P Guay

1

1 reference

3 August 2017

publication date

1 April 2002

1 reference

3 August 2017

published in

Clinical Therapeutics

1 reference

3 August 2017

volume

24

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

473-489

1 reference

FK 482, a new orally active cephalosporin synthesis and biological properties

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Morphological alterations of Staphylococcus aureus and Streptococcus pyogenes exposed to cefdinir, a new oral broad-spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro antibacterial activity of FK041, a new orally active cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

The effects of quinolones on the adherence of type-1 fimbriated Escherichia coli to mannosylated agarose beads.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

The in-vitro activity of cefdinir (FK482), a new oral cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro activity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro antibacterial activity of FK482, a new orally active cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparative in-vitro activity of cefdinir against multiresistant Haemophilus influenzae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro and In vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro and in vivo antibacterial activity and pharmacokinetics of SC-002 and its derivative, SC-004: new oral cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Post-antibiotic effects of cefdinir on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pyrogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Stability of cefdinir (C1-983, FK482) to extended-spectrum plasmid-mediated beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparison of cefdinir and penicillin V in the treatment of pediatric streptococcal tonsillopharyngitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Cefdinir vs. amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Efficacy and safety of cefdinir in the treatment of maxillary sinusitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis. The Cefdinir Bronchitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Impairment of cefdinir absorption by iron ion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Red stools and omnicef

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI 983), on human peripheral mononuclear and polymorphonuclear leukocyte functions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Cefdinir-induced modification of the susceptibility of bacteria to the antibacterial activity of human serum and polymorphonuclear neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985125-6

7 January 2021

10.1016/S0149-2918(02)85125-6

Identifiers

DOI

1 reference

3 August 2017

1 reference